

## DAFTAR PUSTAKA

1. Proietti M, Airaksinen KEJ, Rubboli A, Schlitt A, Kiviniemi T, Karjalainen PP, et al. Time in therapeutic range and major adverse outcomes in atrial fibrillation patients undergoing percutaneous coronary intervention: The Atrial Fibrillation Undergoing Coronary Artery Stenting (AFCAS) registry. *American Heart Journal*. 2017;190(6):86–93.
2. Zielonka A, Tkaczyszyn M, Mende M, Nowak W, Rekucki K, Soczomska P, et al. Atrial fibrillation in outpatients with stable coronary artery disease: Results from the multicenter RECENT study. *Polskie Archiwum Medycyny Wewnetrznej*. 2015;125(3):162–71.
3. Kralev S, Schneider K, Lang S, Süselbeck T, Borggrefe M. Incidence and severity of coronary artery disease in patients with atrial fibrillation undergoing first-time coronary angiography. *PLoS One*. 2011;6(9).
4. Kirchhof P, Benussi S, Koteka D, Ahlsson A, Atar D, Casadei B, et al. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. *European Heart Journal*. 2016;37(38):1-7.
5. Fischer Q, Georges JL, Le Feuvre C, Sharma A, Hammoudi N, Berman E, et al. Optimal long-term antithrombotic treatment of patients with stable coronary artery disease and atrial fibrillation: “OLTAT registry.” *International Journal of Cardiology*. 2018;264:64–9.
6. Lamberts M, Gislason GH, Lip GYH, Lassen JF, Olesen JB, Mikkelsen AP, et al. Antiplatelet therapy for stable coronary artery disease in atrial fibrillation patients taking an oral anticoagulant: A nationwide cohort study. *Circulation*. 2014;129(15):1577–85.
7. Fauchier L, Lecoq C, Clementy N, Bernard A, Angoulvant D, Ivanes F, et al. Oral anticoagulation and the risk of stroke or death in patients with atrial fibrillation and one additional stroke risk factor: The Loire Valley atrial fibrillation project. *Chest*. 2016;149(4):960–8.
8. Albayrak S, Ozhan H, Aslantas Y, Ekinözü I, Tibilli H, Kayapınar O. Predictors of major adverse cardiovascular events ; results of population based MELEN study with prospective follow-up. *European Review for Medical and Pharmacological Sciences*. 2015;1446–51.
9. Pranata R, Deka H, Siswanto BB. Cardiovascular and Neurological Complications Associated with Atrial Fibrillation. *Jurnal Kardiologi Indonesia*. 2016;37(3):164–72.
10. Yuniadi Y, Tondas AE, Hanafy DA, Hermanto DY, Maharani E, Munawar M, et al. Pedoman Tata Laksana Fibrilasi Atrium. Jakarta: Perhimpunan Dokter Spesialis Kardiovaskular Indonesia. 2014. 32 p.
11. Effendi. Tata laksana Fibrilasi Atrium. *Cdk-249*. 2017;2(2):94.
12. Yansen I, Yuniadi Y. Tata Laksana Fibrilasi Atrium : Kontrol Irama atau Laju Jantung. *Cdk-202*. 2013;40(3):171–5.

13. Camm AJ, Amarenco P, Haas S, Hess S, Kirchhof P, Kuhls S, et al. XANTUS: A real-world, prospective, observational study of patients treated with rivaroxaban for stroke prevention in atrial fibrillation. European Heart Journal. 2016;37(14)11. 2016;37(14):1145–53.
14. Yuniadi. Tatalaksana Pasien Fibrilasi Atrium, Pusat Jantung Nasional Harapan Kita, Jakarta. 2014;
15. Brandes A, Smit MD, Nguyen BO, Rienstra M, Van Gelder IC. Risk Factor Management in Atrial Fibrillation. Arrhythmia Electrophysiology Review. 2018;7(2):118–27.
16. Staerk L, Sherer JA, Ko D, Benjamin EJ, Helm RH. Atrial Fibrillation: Epidemiology, Pathophysiology, Clinical Outcomes. Circulation Research. 2017;120(9):1501–17.
17. Rilantono LI. Penyakit Kardiovaskular. 1st ed. Rahajoe AU, Karo-karo S, editors. Jakarta: Badan Penerbit Fakultas Kedokteran Universitas Indonesia; 2012. 395 p.
18. Wijaya C. Hubungan Amplitudo Gelombang Fibrilasi dengan Irama kembali ke Sinus pada Pasien Non Valvular Recent Onset Atrial Fibrillation. JIK. 2017;11(1):25–30.
19. Aviles R, Martin D, C A-H, Al E. Inflammation as A Risk Factor of Atrial Fibrillation. Circulation Research. 2013;
20. Markides V. Atrial fibrillation: classification, pathophysiology, mechanisms and drug treatment. Heart. 2003;89(8):939–43.
21. Rampengan SH. Kardioversi Pada Fibrilasi Atrium. Jakarta: Badan Penerbit Fakultas Kedokteran Universitas Indonesia; 2015. 14-30 p.
22. Iwasaki YK, Nishida K, Kato T, Nattel S. Atrial fibrillation pathophysiology: Implications for management. Circulation. 2011;124(20):2264–74.
23. Fuster V, Ryden L, Cannom D, Crijns H, Curtis A, Ellenbogen K. Guidelines for The Management of Patients with Atrial Fibrillation. ACC/AHA/ESC 2006. 2006;
24. Kirchhof P, Benussi S, Zamorano JL, Aboyans V, Achenbach S, Agewall S, et al. 2016 ESC guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Vol. 147, Russian Journal of Cardiology. 2017. 7-86 p.
25. Kim Y-H, Roh S-Y. The Mechanism of and Preventive Therapy for Stroke in Patients with Atrial Fibrillation. Journal of Stroke. 2016;18(2):129–37.
26. Roveny. Antikoagulan untuk Stroke Iskemik Kardioemboli. Continuing Development Professional Medical Development. 2015;42(5):345–9.
27. Jamaluddin AN b, Alias A bt, Ros A b R. Clinical Practice Guidline of Atrial Fibrillation. National Heart Association of Malaysia. 2012;12;6-10

28. Department of Health. Guidelines for Warfarin Management in the Community. Australia: State of Queensland (Queensland Health) and the Royal Flying 2012. 1-23 p.
29. Craig T. January, MD, PHD, FACC C, L. Samuel Wann, MD, MACC, FAHA VC et al. 2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation: Executive Summary. Vol. 64, Jacc. 2014. 0735-1097 p.
30. Syarif A, Estuningtyas A, Setiawati A, Muchtar A, Ascobat P, Setiabudy R, et al. Farmakologi dan Terapi. 5th ed. Gunawan SG, Setiabudy R, Nafrialdi, Elysabeth, editors. Jakarta: Badan Penerbit Fakultas Kedokteran Universitas Indonesia; 2007.810-12 p.
31. Limdi NA, Veenstra DL. Warfarin Pharmacogenetics. Pharmacotherapy: A Pathophysiologic Approach, 8e. 2009;28(9):1084–97.
32. Agustini TT, Arifin H, Hanif AM. Comparison between Warfarin Dose with Duration Achieving Target INR in Patient with CHF and Atrial Fibrillation. Jurnal Sains Farmasi dan Klinis. 2016;2(2):162–70.
33. Van Ryn J, Stangier J, Haertter S, Liesenfeld KH, Wienen W, Feuring M, et al. Dabigatran etexilate - A novel, reversible, oral direct thrombin inhibitor: Interpretation of coagulation assays and reversal of anticoagulant activity. Thrombosis Haemostasis. 2010;103(6):1116–27.
34. Medscape. Dabigatran (Pradaxa) [Internet]. [cited 2018 Nov 12]. Available from: <https://reference.medscape.com/drug/pradaxa-dabigatran-342135#10>
35. Comin J, Kallmes DF. Pharmacology vignette, Dabigatran (Pradaxa). American Journal of Neuroradiology. 2012;426–8.
36. Sunkara T, Ofori E, Zarubin V, Caughey ME, Gaduputi V, Reddy M. Perioperative Management of Direct Oral Anticoagulants (DOACs): A Systemic Review. Health Services Insights. 2016;9s1:HSI.S40701.
37. Irawati, Sylvi. Apixaban: Antikoagulan Oral Baru-Penghambat Spesifik Faktor Xa. Medikamen. 2014;(22).1-4.
38. Force T, Gilles M, Chairperson M, Sechtem U, Germany C, Germany SA, et al. 2013 ESC guidelines on the management of stable coronary artery disease The Task Force on the management of stable coronary artery disease. 2013;2949–3003.
39. Scottish Intercollegiate Guideline Network (SIGN). Management of stable angina. Edinburgh: SIGN; 2018.26-28 p.
40. Lluís-ganella C. Pathogenesis of coronary artery disease : focus on genetic risk factors and identification of genetic variants. 2014;15–32.
41. Robbins S, Cotran R, Kumar V. Buku Ajar Patologi Robbins. 7th edition. Hartanto H, Darmaniah N, Wulandari N, editors. Jakarta: EGC; 2013. 369-378 p.

42. Ford TJ, Corcoran D, Berry C. Stable coronary syndromes: pathophysiology , diagnostic advances and therapeutic need. Heart. 2018;(CMD):284–92.
43. Hendel RC, Jabbar AY, Mahata I. Initial diagnostic evaluation of stable coronary artery disease: The need for a patient-centered strategy. Journal of the American Heart Association. 2017;6(7):1–3.
44. Irmalita, Juzar DA, Andrianto, Setianto BY. Pedoman Tatalaksana Sindrom Koroner Akut. Jakarta: Perhimpunan Dokter Spesialis Kardiovaskular Indonesia. 2015;1-41 p.
45. Golwala HB, Cannon CP, Steg PG, Doros G, Qamar A, Ellis SG, et al. Safety and efficacy of dual vs. triple antithrombotic therapy in patients with atrial fibrillation following percutaneous coronary intervention: A systematic review and meta-analysis of randomized clinical trials. European Heart Journal. 2018;39(19):1726–35.
46. Akao M. Atrial fibrillation and coronary artery disease: Resembling twins ?. Journal of Cardiology. 2014;63(2):169–70.
47. Smith SC, Benjamin EJ, Bonow RO, Braun LT, Creager MA, Franklin BA, et al. AHA/ACCF secondary prevention and risk reduction therapy for patients with coronary and other atherosclerotic vascular disease: 2011 update: A guideline from the American Heart Association and American College of Cardiology Foundation. Circulation. 2011;124(22):2458–73.
48. Lip GYH, Windecker S, Huber K, Kirchhof P, Marin F, Berg JMT, et al. Management of antithrombotic therapy in atrial fibrillation patients presenting with acute coronary syndrome and/or undergoing percutaneous coronary or valve interventions: A joint consensus document of the European Society of Cardiology Working Group on Thrombosis, European Heart Rhythm Association (EHRA), European Association of Percutaneous Cardiovascular Interventions (EAPCI) and European Association of Acute Cardiac Care (ACCA) endorsed by the Heart Rhythm Society (HRS) and Asia-Pacific Heart Rhythm Society (APHRS). European Heart Journal. 2014;35(45):3155–79.
49. Hicks KA, Hung HMJ, Mahaffey KW, Mehran R, Nissen SE, Stockbridge NL, et al. Standardized Definitions for Cardiovascular and Stroke Endpoint Events in Clinical Trials. Draft Definition for CDISC. 2014;1–33.
50. Lin Y, Liu P, Wu L, Chen Y, Chang C, Chu P. Major adverse cardiovascular events in adult congenital heart disease : a population-based follow-up study from Taiwan. BMC Cardiovascular Disorder. 2014;14:38
51. De Groot B, Van Den Berg S, Kessler J, Ansems A, Rijpsma D. Independent predictors of major adverse cardiovascular events in emergency department patients who are hospitalised with a suspected infection: A retrospective cohort study. BMJ Open. 2016;6(1).1-8.

52. Schulman S, Kearon C. Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients. Subcommittee on control of anticoagulation of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis. *Journal of Thrombosis and Haemostasis*. 2005;3(4):692–4.
53. Pastori D, Pignatelli P, Saliola M, Carnevale R, Vicario T, Del Ben M, et al. Inadequate anticoagulation by Vitamin K Antagonists is associated with Major Adverse Cardiovascular Events in patients with atrial fibrillation. *International Journal of Cardiology*. 2015;201:513–6.
54. Violi F, Soliman EZ, Pignatelli P, Pastori D. Atrial Fibrillation and Myocardial Infarction: A Systematic Review and Appraisal of Pathophysiologic Mechanisms. *Journal of the American Heart Association*. 2016;5(5):1–13.
55. Dahlan MS. Besar Sampel dan Cara Pengambilan Sampel dalam Penelitian Kedokteran dan Kesehatan. Jakarta: Salemba Medika; 2010.
56. Goto K, Nakai K, Shizuta S, Morimoto T, Shiomi H, Natsuaki M, et al. Anticoagulant and antiplatelet therapy in patients with atrial fibrillation undergoing percutaneous coronary intervention. *American Journal of Cardiology*. 2014;114(1):70–8.
57. Motloch LJ, Reda S, Larbig R, Wolff A, Motloch KA, Wernly B, et al. Characteristics of coronary artery disease among patients with atrial fibrillation compared to patients with sinus rhythm. *Hellenic Journal of Cardiology*. 2017;58(3):204–12.
58. van der Kuip DAM, Hofman A, Stricker BHC, Witteman JCM, Stijnen T, van Herpen G, et al. Prevalence, incidence and lifetime risk of atrial fibrillation: the Rotterdam study. *European Heart Journal*. 2006;27(8):949–53.
59. Bai Y, Zhu J, Yang YM, Liang Y, Tan HQ, Wang J, et al. Clinical characteristics and one year outcomes in Chinese atrial fibrillation patients with stable coronary artery disease: A population-based study. *Journal of Geriatric Cardiology*. 2016;13(8):665–71.
60. Wong JA, Rexrode K, Sandhu RK, Moorthy MV, Conen D, Albert CM. Menopausal Age, Postmenopausal Hormone Therapy and Incident Atrial Fibrillation. *HHS Public Access*. 2018;103(24):1954–61.
61. Jensen TB, Gislason GH, Andersson C, Ahlehoff O, Hansen PR, Bretler D-M, et al. Hormone Replacement Therapy and Risk of New-Onset Atrial Fibrillation after Myocardial Infarction - A Nationwide Cohort Study. *PLoS One*. 2012;7(12):e51580.
62. Tsai WC, Haung Y Bin, Kuo HF, Tang WH, Hsu PC, Su HM, et al. Hormone replacement therapy and risk of atrial fibrillation in Taiwanese menopause women: A nationwide cohort study. *Sci Rep*. 2016;6(March):1–9.

63. Fauchier L, Greenlaw N, Ferrari R, Ford I, Fox KM, Tardif JC, et al. Use of anticoagulants and antiplatelet agents in stable outpatients with coronary artery disease and atrial fibrillation. International CLARIFY registry. PLoS One. 2015;10(4):1–23.
64. Capodanno D, J. Angiolillo D. Advances in Interventional Cardiology Management of Antiplatelet and Anticoagulant Therapy in Patients With Atrial Fibrillation in the Setting of Acute Coronary Syndromes or Percutaneous. Interventions Coronary. 2014;113–24.
65. Pogue J, Morais J, De Caterina R, Yusuf S, Connolly SJ, Renda G, et al. Mortality predictors and effects of antithrombotic therapies in atrial fibrillation: insights from ACTIVE-W. European Heart Journal. 2010;31(17):2133–40.
66. Olivier CB, Turakhia MP, Mahaffey KW, Olivier CB, Turakhia MP, Mahaffey KW, et al. Expert Opinion on Drug Safety Anticoagulant and antiplatelet therapy choices for patients with atrial fibrillation one year after coronary stenting or acute coronary syndrome one year after coronary stenting or acute coronary syndrome. Expert Opinion of Drug Safety. 2018;00(00):1–8.
67. HAMM CW. The ACTIVE Writing Group on behalf of the ACTIVE Investigators\*. 1903;1903–12.
68. Gao F, Zhou YJ, Wang ZJ, Yang SW, Nie B, Liu XL, et al. Meta-analysis of the combination of warfarin and dual antiplatelet therapy after coronary stenting in patients with indications for chronic oral anticoagulation. International Journal of Cardiol. 2011;148(1):96–101.
69. Zhao HJ, Zheng ZT, Wang ZH, Li SH, Zhang Y, Zhong M, et al. “Triple therapy”rather than “triple threat”: A meta-analysis of the two antithrombotic regimens after stent implantation in patients receiving long-term oral anticoagulant treatment. Chest. 2011;139(2):260–70.